Dr. Jack Weldon McAninch, MD

Dr. McAninch practices at Zuckerberg San Francisco General Hospital and Trauma Center in San Francisco, California, part of City and County of San Francisco, CA.

Dr. McAninch's NPI, 1164476628, was assigned on May 20, 2006. Dr. McAninch graduated from UTMB Health in 1964. Dr. McAninch holds California license G14761.

Dr. McAninch's primary practice is Zuckerberg San Francisco General Hospital and Trauma Center, at 1001 Potrero Avenue, San Francisco, CA 94110 in San Francisco County. The practice phone is (415) 206-8000.

Dr. McAninch's primary practice is Zuckerberg San Francisco General Hospital and Trauma Center in San Francisco, California, part of City and County of San Francisco, CA. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. McAninch to 3 more medical groups, each named with a free account. Dr. McAninch's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McAninch practices. Vendor and product names are available with a free account.

Urology is Dr. McAninch's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. McAninch is board certified in urology by the American Board of Urology. Dmand AI has Dr. McAninch's licenses on file in 4 states: California, Massachusetts, Texas and Iowa.

Dmand AI lists urinary endoscopy among the conditions Dr. McAninch treats.

CMS data shows 44 Medicare services from Dr. McAninch across 3 procedure codes in 2024, for 58 Medicare patients. Medicare paid $2,450 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 58 Medicare patients who saw Dr. McAninch in 2024. The largest group is 65 to 74, with 38 patients. 69% of them have high blood pressure, and 59% have high cholesterol. Their average risk score is 2.03, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McAninch's median patient age at 74, with 15% women.

In 2024, Dr. McAninch wrote 21 Medicare Part D claims for 15 patients. 100% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $32 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. McAninch for performance year 2024, reported as part of a group. Dr. McAninch accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 29 papers to Dr. McAninch, published from 2010 to 2025. 2015 was the busiest year, with 4. The most frequent topics are Kidney, Urethra and Urethral Stricture. Dr. McAninch has published most often in J Urol. Dr. McAninch's most frequent co-authors are Benjamin Newell Breyer, MD, Catherine Rand Harris, MD and Lindsay Ann Hampson, MD.

Dmand AI links Dr. McAninch to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Urethral Stricture and Urethral Obstruction. Open Payments lists research payments to Dr. McAninch that name 1 trial.

CMS Open Payments shows 8 general payments to Dr. McAninch from 4 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 100% of the total. Boston Scientific Corporation paid the most, $428. It also lists 1 research payment totaling $4,200 in 2022, naming 1 clinical trial.

Dmand AI lists 3 awards for Dr. McAninch.

Dr. McAninch graduated from UTMB Health in 1964. Dr. McAninch is a member of ACS.

Dr. McAninch is in network with 10 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.